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Abstract 
Background: Management of patients with mental disorders is inadequate in the majority of low and middle 
income countries. The main treatment modality for patients with severe mental disorders in these countries is mainly 
pharmacological approach. Patients face many challenges in meeting medication needs. In this context, high per-
centages of individuals who have severe mental disorders are not treated. Regular and adequate supplies of appropri-
ate, safe and affordable medications are some of the important aspects required for provision of quality mental health 
services. Psychotropic medications are an important component of holistic care that provides treatment options for 
those suffering from mental illnesses. In Tanzania, mental health services face many challenges including inadequate 
mental health care providers, infrastructure, and medication supply. Relapse is a common problem among patients 
attending mental health facilities. This study is aimed at exploring views and experiences of patients, caregivers and 
mental health care providers on the psychotropic medication in Dar es Salaam, Tanzania
Methods: A qualitative study was conducted, involving two focus group discussions with seven and nine caregiv-
ers in each group. Eleven in-depth interviews with four patients and seven mental health care providers at Temeke 
Municipality, Dar es Salaam, were conducted. Convenient sampling procedure was used to select participants for the 
study. Discussion and interview guides were used during data collection. Interviews were audio-recorded in Kiswahili 
with all study participants. The recorded interviews were transcribed and qualitative content thematic analysis was 
used to analyze data after translation.
Results: Four themes were identified. These include attitudes of patients towards psychotropic medication, availabil-
ity of psychotropic medications, financial concerns towards psychotropic medications, and coverage of free treatment 
policy.
Conclusion: The availability and affordability of psychotropic medications to patients are big problems. This was 
partly attributed to insufficient funds to support the budget of health facilities and technical challenges contributed 
by both the health facilities and other stakeholders. To improve mental health services in the country, it is important 
to ensure adequate supply of psychotropic medications in the health facilities. Access to psychotropic medications 
is essential in addressing the public health problem of untreated mental illnesses. These findings call for the govern-
ment and other stakeholders to increase funding for essential psychotropic medications.
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Background
Treatment of patients with severe mental illness is inade-
quate in most low and middle income countries (LMICs). 
High percentages of individuals who have severe men-
tal disorders such as bipolar disorder, major depressive 
disorder and schizophrenia, remain untreated [1]. In 
addition to this disease burden, LMICs face many chal-
lenges in meeting mental health needs in their regions. 
Emphasis has been put on the role for both psychosocial 
and pharmacological management of mental illnesses [2]. 
However, psychosocial management is almost non-exist-
ent and pharmacological therapy is the most common 
treatment method in many government-funded health 
facilities [3, 4]. It is also important to note that psychoso-
cial, together with biological treatments, have proven to 
be effective in low resource settings [5].
One of the biggest challenges to provision of services to 
the people with mental illness in low and middle income 
countries is that of ensuring regular and adequate supply 
of appropriate, safe, and affordable medications. Psycho-
tropic medications are important component of holistic 
care that provides treatment options for those suffering 
from mental illnesses [3]. Studies have reported that lack 
of up-to-date data on the availability of effective and effica-
cious medications for mental healthcare in these countries 
is a major problem that inhibits quality patient care [4, 5].
In Tanzania, most health facilities are not equipped 
with enough resources, which include a continuous sup-
ply of essential psychotropic medications that could help 
improve quality of mental health care.
Mental health services are provided free of charge. 
However, relapse problems with mental health clients 
attending the district health facilities are very common. 
The most important factors contributing to relapse 
include non-adherence to medication, side effects, and 
inadequate knowledge on management of symptoms 
among patients and family members [6–8].
The free services for mental health is not realised in 
most health services in low and middle income countries, 
especially when it comes to availability of cost effective 
medications. Studies in other countries report that direct 
out-of-pocket payment by patients is required in order to 
get prescribed medication which is not available for free 
in the government pharmacies [4, 5, 9]. The need of med-
ication is important to control symptoms, which may be 
frustrating to the patient and caregiver if not controlled. 
A study in Tanzania revealed difficulties in accessing 
medication by the patient due to high cost of getting 
them in pharmacies outside the hospital [10].
For the benefit of the patient with mental disorders, 
health systems have an important role to play in facili-
tating access to psychotropic medicine in any country. 
A cross sectional analysis of 63 low and middle income 
countries suggested that strengthening particular aspects 
of mental health systems may lead to improved avail-
ability of psychotropic medicines, and that the over-
all country development is associated with medication 
affordability [11]. This implies that governments have not 
invested much in mental health systems. Evidence reveals 
that there is minimal government spending on men-
tal health services in most LMICs (1–2% of the health 
budget), despite having large numbers of people in need 
of the services [12].
The existence of a comprehensive national mental 
health plan in most of the countries has been found to 
facilitate improvement in access to psychotropic medica-
tions [13]. This plan guides countries on how the health 
system can be more user friendly, especially in accessing 
mental health services. Additionally, the World Health 
Organization (WHO) has listed factors that are impor-
tant for improving access to psychotropic medications. 
These include rational selection of the medicine, afford-
able price, longstanding financing, and reliable health 
and supply systems [14]. In most of the countries, sup-
ply of psychotropic medication to rural health facilities is 
not sufficient. There are many factors that contribute to 
inadequate supplies of psychotropic medicine in most of 
government health facilities. Inadequate funding, lack of 
priorities, perception and past experience of prescribers 
has been reported to be important factors in many coun-
tries in LMIC [9].
This study explored the experiences and views of 
patients, caregivers and health care providers in meeting 
medication needs of people with mental illness.
Methods
Study design
This was a qualitative study that explored experiences and 
views of patients, health care providers and caregivers on 
medication needs of patients with mental disorders.
Study site
The study was conducted in Temeke Municipal Hospi-
tal which is one of the hospitals in Temeke District, Dar 
es Salaam. Dar es Salaam is very fast growing and is the 
largest commercial city in Tanzania with the population 
of more than six million. Temeke district had a popula-
tion of 1,368,881 as per demographic and population 
Census of 2012. Socio-economic characteristics of this 
area that are likely to influence the occurrence of mental 
health problems/disorders includes the fact that most of 
youth from other regions in the country move to this area 
with high expectation of getting employment. However, 
most of them are unable to obtain employment and as a 
result of this disappointment become involved with ille-
gal drug business and drug abuse.
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Sample size and sampling procedure
A convenient sampling was used to obtain four patients, 
sixteen caregivers, and seven health care providers. 
Patients were recruited through Temeke Municipal Hos-
pital as they attended the mental health clinic. Caregivers 
were obtained through patients as they escorted them to 
the clinic. The mental health coordinators were obtained 
in their respective offices. The sample size was deter-
mined by saturation point, i.e. when there was no new 
information obtained from the informants.
The following inclusion criterion was used to get 
participants:
1. Health care providers who have been working in the 
mental health clinics for at least 3 years.
2. Patients who had a chronic mental illness and who 
were mentally stable at the time of interview (i.e. with 
insight and able to communicate properly). These 
were identified using a quick mental state evaluation, 
which is a standard mental health test.
3. Main caregivers who stayed with a patient with men-
tal illness for at least 6 months.
4. Participants were aged 18 years and above.
Exclusion criteria included the following:
1. Caregivers with communication problems.
2. Health care providers who were on leave during data 
collection.
Ethical consideration
The ethical clearance of the study was obtained from 
the Directorate of Research and Publication Commit-
tee of the Muhimbili University of Health and Allied 
Sciences. Permission to conduct the study was sought 
from the Regional Administrative Officer and lower 
authorities in the region including district medi-
cal officer and hospital in-charge. Participants were 
informed about the study procedures. Their role and 
expectations in the study as participants were clearly 
stated. Written informed consent was sought from 
participants. The consent was obtained prior to inter-
view sessions. For people with mental illness, informed 
consent was first sought from their caregivers. All par-
ticipants agreed to participate and signed the consent 
form. They also consented to be audio recorded during 
the discussion and interview.
Their role and expectations in the study as partici-
pants were clearly stated. Confidentiality was guaranteed 
by identifying participants using numbers and not their 
names. They were also assured that the audiotapes, tran-
scripts, and written notes containing the participants’ 
information would be kept well in a safe place and only 
the researchers would have access to information and 
would be destroyed later after completion of the study.
Data collection
Data collection took place on hospital premises. Focus 
group discussions (FGDs) and in-depth interviews were 
used during data collection. In-depth interviews were 
conducted with mental health care workers and coor-
dinators, and patients attending mental health clinics at 
the health facility. FGDs were conducted among caregiv-
ers. The venue for both discussion and interviews was 
carefully chosen to ensure that it is a quiet place with no 
distractions. Both groups provided information on their 
experience and views about challenges encountered on 
meeting medication needs.
Eleven in-depth interviews including five health care 
providers, two mental health coordinators and four 
patients, while two FGD with seven caregivers in FGD 
1 and 9 and nine caregivers in FGD 2, participated in 
discussions. The mental health coordinators were inter-
viewed in their respective offices.
The duration of in-depth interviews was between 
30 and 45  min, while for FGDs it was between 45 and 
60 min. FGDs were conducted in order to get views from 
caregivers of patients with mental illness on support they 
provide at home especially meeting medication needs. 
Female and males caregivers were interviewed separately 
to facilitate free expression as a principle of a homoge-
nous group. Questions that were asked during data col-
lection were as follows:
For mental health care providers and coordinators
1. What is your experience at the health facility in pro-
viding mental health services to patients?
2. How is your health facility prepared to meet psycho-
tropic medication needs of patients?
3. What do you think should be done to improve access 
to psychotropic medication in your facility?
For patients
1. What is your experience in getting mental health ser-
vices in this hospital, especially with regard to medi-
cation?
2. Are you satisfied? And why?
3. What do you think should be done to improve men-
tal health services in this hospital, especially medica-
tion?
For caregivers
1. What do you think are the needs of a mentally ill 
patient at home?
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2. What are your views about how psychotropic medi-
cation needs are met by your patient?
3. What support have you been providing to your 
patient with regard to medication need and what are 
the challenges faced?
Each question, in all interviews, was followed by sev-
eral probes to elicit more information on the matter in 
question.
Both types of data collection were conducted in Swa-
hili, which is a common language to all participants, 
and all interviews were digitally audio-recorded. Data 
that was not easily captured by the audio recorder, such 
as non-verbal cues and environmental events, was wr 
downitten in the note book. In case of FGDs, the moder-
ator (researcher) was leading the discussion and kept the 
conversation flowing. A research assistant was helping to 
record the interviews and take notes.
Data analysis
All the audio data was transcribed verbatim and then 
translated into English. The content analysis method, in 
accordance with qualitative analytical framework, was 
used to analyse data which involved the researchers read-
ing and re-reading the text. NVivo 10 software was used 
in organizing data and coding the text. The coded text 
was filtered and placed in similar contents that formed a 
tree node. The identified content of the text was entered 
into memos which were eventually manually organized 
into codes and themes as in the Fig. 1.
Trustworthiness
Credibility of the data collected was addressed by 
employing two methods of data collection i.e. use of 
FGDs and in-depth interviews, and also, that data was 
obtained from different sources such as patients, health 
care workers and caregivers. The interview guide was 
used to ensure consistency during data collection.
Results
Characteristics of participants
The study was comprised of three groups of participants; 
mental health care workers (MHCW), caregivers (CG) 
and patients (PT).
The health care workers included two assistant medi-
cal officers (AMO), 3 Nurses, one social workers (SW), 
the district mental health coordinator (DMHC), and 
the National mental health coordinator (NMHC) (see 
Table  1). Among the nurses who were interviewed, one 
was a nursing officer, two were senior nursing officers 
and one was working as social worker.
Every participant had a working experience of more 
than 3  years in that position and all were working in 
the mental health clinic. There were four patients (see 
Table 2) and sixteen caregivers (see Table 3).
Themes identified
The following themes emerged after data analysis; atti-
tudes of patients towards psychotropic medication, avail-
ability of psychotropic medications, Financial concerns 
towards psychotropic medications and coverage of free 
treatment policy
Attitudes of patients towards psychotropic medication
Most participants were satisfied with the therapeutic 
effects of psychotropic medication. Patients and caregiv-
ers appreciated the changes experienced or observed 
just after starting treatment at the health facility. Oth-
ers, however, had mixed beliefs on the effectiveness of 
the psychotropic medications. They expected instant 
Fig. 1 The coding process and formation of themes














Duration of work experience
 3–12 years 2
 13–22 3
 23–32 2
 33 and above 0
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therapeutic effect that could bring changes to the patient. 
When they failed to see these changes immediately, they 
were likely to seek alternative treatment, especially from 
traditional healers.
“Since he began to get medicine this month he has 
calmed down a bit, as the previous incidences are 
not available anymore. He is doing fine and has 
insights” (FGD 1 CG No 2)
“……You see, there are those who benefit and those 
who do not benefit from these medications. Those 
who feel delayed therapeutic effects they often seek 
traditional treatment” (FGD 2 CG No 7)
Caregivers reported being troubled with patients’ 
symptoms. They were compelled to bring the patient 
to the hospital when they needed to stabilize patient’s 
symptoms. They expressed satisfaction with getting psy-
chotropic medication particularly when the symptoms 
that caused the patients to stay awake during the night 
disappeared.
“….then the family members are very careful to 
ensure that the prescribed medications are taken 
accordingly. Now the patient is doing fine” (FGD 2 
CG No 4)
The patients also reported that the psychotropic agents 
prescribed were a good booster of inducing sleep as 
stated by a patient with bipolar disorder;
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“Before starting to use the medicine I was not able to 
sleep. I was just staying awake throughout the night 
but now I am able to sleep” (Female Pt with BPD)
Availability psychotropic medications at the health facility
The availability of medications, as expressed by most 
participants, was a major challenge. Patients, caregivers, 
health care workers, and coordinators acknowledged that 
medications were not readily available at the facility due 
to various reasons including inadequate budget and not 
being available at the main store in the hospital.
Health care workers working in the hospital expressed 
the availability of psychotropic medications as unpredict-
able. Lack of medication sometimes made patients angry 
and feel that health workers were reluctant to issue medi-
cation as described by a nurse:
“There is no psychotropic medication and sometimes 
patients become angry and therefore use abusive 
language towards the health worker, like ‘why don’t 
you give us medication?’… Sometimes medicines 
become available but now it has been four or five 
months with no essential psychotropic medicines. 
There is no medication for patients with schizophre-
nia and epilepsy; the medicines that are most often 
used” (HCW Nurse)
Another health worker added:
“We do not get atypical antipsychotics; the antipsy-
chotic that saves here is only CPZ (Chlopromizine). 
If this medicine is out of store (not available), then 
you get fever (confused; not knowing what to do) 
because haloperidol itself is very rarely available” 
(HCW–AMO)
This problem was noted by the district mental health 
coordinator, showing the importance of having a contin-
uous supply of medication in the hospital pharmacy due 
to the fact that most patients do not afford to buy pre-
scribed medications.
“There is no continuous supply of medicine that 
patients need to get from the hospital. They are told 
to go and buy outside the hospital. You find that the 
patient cannot afford to buy the prescribed medica-
tion” (DMHC).
Caregivers also expressed similar concerns. They 
explained the challenges they face particularly when 
they do not get free medications for their patients from 
the hospital. Atypical antipsychotics, which have fewer 
side eAttitudes of patients towards psychotropic medi-
cation effect profiles, were the most unavailable medi-
cations described by the participants. Although these 
antipsychotics are not frequently prescribed as first line 
drug, they are rarely available in the government pharma-
cies. When the medicine is out of stock (not available), 
patients are instructed to buy from non-governmental 
pharmacies. One participant whose patient used more 
than one medication desperately stated;
“The main challenge here in this hospital is avail-
ability of medicine. They just tell you that the medi-
cine is finished, you need to buy and this is not only 
once, very often. You have to incur the cost which is 
so high. For example, what I know, my patient uses 
two types of medicines, I do not know its name, this 
one is available but the other one, Olanzapine(drug 
for treatment of schizophrenia) is quite unavailable 
here in the hospital” (FGD 1 CG No 3).
On the other hand, patients were the most vulnerable 
population and were directly affected by the shortage of 
medicine. Patients, especially those who came alone for 
medicine refill, suffered the most because, with all the 
risks of transport problems and other urban challenges, 
they were told to go and look for medication outside the 
hospitals as expressed by a patient with bipolar disorder:
“So the chief challenge here is medicine, most of the 
time we are told to buy medicine because here in the 
hospital it is not available. Remember, I have come 
alone but I have to go and look for non-government 
pharmacy to buy my the medication” (Male Pt with 
BPD)
Reasons for inadequate medication
The procurement process by the hospital and then the 
ordering by the mental health department was a long 
process that which was said to be the reason for inad-
equate availability of medications. It was overtaken by 
the rapid requirements of the medicine by patients. So 
the mental health department could order the medicines, 
but due to the complicated process of procurement, the 
ordered medicines may not be available as expressed by 
one of the mental health provider:
“Usually, when the medicine reaches at the hospital 
pharmacy, what we normally do is ordering. When 
you order the medicine, you find that it is not avail-
able. Sometimes when you order, they bring very few 
medicines for mental health which do not suffice the 
needs of patients. That’s why you find that we run 
out of stock (short of medication) very often” (HCW 
Nurse).
Sometimes the unavailability of medicine was attrib-
uted to the small budget set aside for this purpose. This 
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small amount of money could purchase very little medi-
cine needed by a large number of patients who attend 
the mental health clinic. In addition, the chronic nature 
of mental illness makes patients use the medications for 
extended period of time, as explained by a mental health 
provider:
“They say perhaps the budget is brought in that way 
(inadequate) but the reality is that psychiatric medi-
cation in our country is a problem, it’s not available, 
and even that little amount brought will not last 
for long because, I understand psychiatric patients 
are prescribed monthly dosages. So if 250 cans are 
bought in a month, will it be enough”? (HCW SW)
The shortage of psychotropic medication was asserted 
to be not only a local but a national problem that 
included other medicines for treatment of various physi-
cal illnesses. However, it was mentioned that efforts were 
being made to make medications available. One of the 
strategies was to reinstate the essential medicine kits 
for primary health care and request all hospital to order 
essential psychotropic medications through cost sharing 
programs before the government took initiatives to get a 
permanent solution as stated by national mental health 
coordinator:.
“So we are in the process to reinstate the essential 
medicine kits, at least to reduce the problems of 
shortage of medicine. In addition, we emphasize that 
every hospital, even if the issue of budget is small, 
can order essential psychotropic medicine for people 
with mental illness through cost sharing when the 
government is working on how to get sufficient medi-
cines. Hospitals have been given mandate of order-
ing the medicine that is needed in the departments 
of mental health according to their needs” (NMHC).
It was suggested that the Ministry of Health needed to 
instruct the lower authorities in the health system such 
as the councils health management team (CHMTs) and 
regional health management team (RCMTs), so that they 
set aside enough money in their budget for medicines 
because they usually set small amounts of money for 
mental health services. They also suggested that due to 
the increasing number of patients daily, there should be 
a basket fund for mental health services that could cover 
the deficit caused by insufficient funds from the central 
government.
“The people in the ministry of health to strengthen 
the issues of budget in the lower levels so that the 
district or regional health councils should set aside 
enough budgets related to mental health” (DMHC)
Another health care worker suggested:
“….If we could have our own basket fund for psychi-
atric patients, we could buy medicine from whole 
sale traders that could help to get enough medicine 
for a while” (HCW AMO)
Financial concerns towards psychotropic medications
Affordability to buy psychotropic medication
Patients, caregivers, health care workers, and coordi-
nators acknowledged the problem of affording to buy 
medication that was not available in the government 
pharmacies. The main reason given was poor economic 
conditions of the patients and caregivers. This was com-
pounded by high prices of medicines in non-governmen-
tal pharmacies.
“I understand that a psychiatric patient is not 
able to buy (medicine), but there are no other ways 
because that is the reality” (HCW Nurse)
Some participants expressed that they ought to buy the 
medication in small quantities depending on the avail-
ability of money, otherwise life would be difficult if they 
would buy all the needed medication dosage at once, as 
described by of the caregiver:
“If we buy all the medicine that he uses, life will con-
tinues to be difficult because the number of medicine 
that is required is twenty or thirty, considering that 
my economic situation is not good. I usually buy 
them in small amounts like 10 tablets to use” (FGD 
2 CG No 2)
Some patients expressed that they had to miss some 
doses as a result of inability to buy the prescribed medi-
cation especially those from poor families and those 
without health insurance.
“…..when you are prescribed a medicine, as you come 
back home you find that there is no money, and I 
may stay five, six or seven days without medication 
until when we get money to buy the medicine” (Male 
PT with BPD)
Another patient added:
“I sometimes get problems because of lack of money, 
but after several days when we get money, then we 
buy half a dose” (Female PT with Schizophrenia)
Although most of the participants described inabil-
ity to buy prescribed medication due to lack of money, 
some parents and patients had expressed knowledge of 
the chronic nature of illness, which they had to set aside 
a budget that could help the patient when they were 
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required to attend the clinic for follow up care and medi-
cine refill.
“Well, when I am prescribed with medications, in 
most cases I usually get prepared for that budget 
because that is illness, you have to get prepared with 
money” (Female PT with Depression)
Health care workers verbalized lack of knowledge 
about mental illness and the importance of professional 
treatment by caregivers and relatives as a factor that con-
tributed to unwillingness to provide financial support to 
patients. Relatives may have the ability to help the patient 
get the required medication but might be reluctant, as 
expressed by one health care worker below:
“They (the relatives) do not know the value of mental 
health. So, if you tell the relative to go and buy medi-
cation for the patient who is aggressive, they think, 
‘ooh! It is wastage of money’, but he does not know 
that the drug is beneficial to the patient” (HCW 
Nurse)
Some caregivers expressed how they managed to buy 
medications through assistance from relatives and other 
people including their partners:
“Thus, I cannot leave my son alone, I have to do 
whatever is possible to send him to the hospital, I see 
different people to beg for financial assistance, they 
contribute money for sending my son to the hospital” 
(FGD 2 CG No 7)
Benefits of health insurance
Health insurance was described as beneficial to patients 
in need of psychotropic medication who could not afford 
to buy it. The situation for patients who had a health 
insurance card was much better than those who did not 
have it. This was said to be more advantageous especially 
for atypical antipsychotics which are more expensive 
than the traditional medicines as described by caregivers 
and a patient:
“…..when he does not get the medicine there (hospi-
tal pharmacy), I take his health insurance card and 
go to take the medicine in a private pharmacy out-
side the hospital. But for those who depend on out 
of pocket payment these medicines are very expen-
sive, and patient should not skip a dose, they needs 
to take every day” (FGD 1 CG No 5).
“I do get the medication in the pharmacy using my 
health insurance card”. (BPD Female PT)
Coverage of free treatment policy
The free treatment policy for a mentally ill patient was 
practiced in the Tanzanian health system. Other groups 
which benefit from this treatment policy include chil-
dren, pregnant mothers and the elderly. In this case, psy-
chiatric patients were exempted from all types of costs, 
including those related to psychotropic medication. 
They were excluded from cost a sharing system that was 
used by other groups of patients with physical illness as 
expressed by one of the health workers below:
“Our patients for example, they do not pay for psy-
chotropic medicines, treatment or various investi-
gations etc. We just fill various needed investiga-
tion forms for the patients and send them to the 
social work office for exemption stamp and then the 
patients go to collect their medicine in the respective 
pharmacy. They (patients) are excluded from cost 
sharing system”. (HCW SW)
Some participants expressed dissatisfaction with the 
exemption system. It was said to be inadequate due to 
frequent lack of essential psychotropic medications. 
Patients and caregivers were expecting free medications 
that could be available and collected at any time, but this 
was not possible. Alternatively, they suggested making 
medications available that could be bought at low price as 
expressed by a caregiver:
“It would be better to bring medications that we can 
buy at low price. I do not know what to do in order 
to get medications at low price if not for free. We are 
really getting problems” (FGD 2 CG No. 9)
Because of the problem of free medication, which was 
in reality not available, one participant suggested that 
patients should contribute a small amount of money that 
could cover the shortage:
“But if for example, there could be a system for 
them (psychiatric patients) to contribute even a 
small amount for buying medication at lower price, 
because here OS (out of stock) is too much, we could 
be able to get stock of medicine”. (HCW AMO)
At the national level, the coordinator described the 
strategies that the ministry was implementing to improve 
the overall health of all Tanzanians. The exemption sys-
tem was said to have been in place for a long time and 
was stated in the Tanzanian mental health policy of 2007
“But the other strategy is the implementation of 
Mental Health Policy of 2007 that openly proclaims 
that psychiatric patients should receive treatments 
free of charge”. (NMHC)
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However, this exemption seemed to be ineffective as 
the provision of medications was not adequate to cater 
for the number of patients who were in need. In most 
cases, the free psychotropic medications were said to be 
unavailable as described by the district mental health 
coordinator:
“Although the mental health services are provided 
free of charge according to national health policy, 
getting psychotropic medicine is a big problem espe-
cially when you consider that most of patients are 
very poor” (DMHC).
Discussion
This study has illuminated an overview of general chal-
lenges related to the availability and affordability of 
psychotropic medications. Participants who were inter-
viewed acknowledged the therapeutic effects of psy-
chotropic medications when used by the patients and 
provided several suggestions for meeting the challenges 
of medication needs.
It is clear that when patients are brought to the health 
facilities, they have a considerable reduction in symp-
toms compared to when they are in traditional treatment.
Positive attitudes towards psychotropic medication
According to the findings from this study, participants 
appreciated the positive effects of psychotropic medica-
tions. This is linked to factors such as perceived efficacy 
or benefit from medicines and the necessity for taking 
treatment. It is also due to the fact that most chronic 
patient with mental illness and their caregivers are ade-
quately educated on the importance of using psycho-
tropic medication. Similar findings have been reported in 
India [15] indicating that biological model of managing 
mental disorders outweighs the other treatment modali-
ties and practice. In addition to this findings, De las Cue-
vas and Sanz in Spain reported that continuous use of 
psychotropic medication shapes the opinion of the users 
toward a more beneficial perception of medications [16]. 
Positive attitudes toward medications among patients 
and caregivers are the most important aspects likely to 
augment adherence to medications and prevent relapse 
of mental illness.
Availability of psychotropic medication
Accessibility of psychotropic medications is an impor-
tant facet that needs to be considered in any nation to 
improve mental health services. According to WHO, 
access of populations to essential psychotropic medi-
cines is determined by a rational selection of medicines, 
making prices affordable, ensuring sustainable financing, 
improved availability and reliable health system and [13].
There are several challenges encountered in meeting 
metal health needs in most of health facilities in low and 
middle income countries. The availability of psychotropic 
medication is one of these challenges as reported in this 
study. In India, similar findings have been reported indi-
cating that availability, distances and cost of medication 
were the main challenges that affect utilization of health 
facilities [14].
This study reported on problems of availability of 
psychotropic medication, contributed by many factors 
including inadequate supply. The reasons for inadequate 
supply of medication reported in this study include 
delays in the procurement process, priority issues, and 
inadequate financing. This is similar to the findings 
reported in Ghana [9], where bureaucracies with the 
process of procurement also affected the availability and 
quality of medications. Because of its importance in con-
trolling psychiatric symptoms, patients need to buy the 
medication outside the hospital pharmacy. The cost of 
medication when obtained outside the hospital is usually 
high which has been reported to affect patients socially 
and financially [17, 18]. Therefore, evidence from this and 
other studies discussed here, point to the need for strat-
egies to ensure the availability of psychotropic medica-
tions in the health facilities. Mental health problems are 
on the increase, so deliberate actions need to be taken 
to make sure drugs are available. Evidence in Tanza-
nia revealed that an inadequate supply of medication is 
one of the factors contributing to relapses of mental ill-
ness in most of patients [7]. The results from this study 
pointed out a need of continuous supply of medication 
to ensure that patients utilize drugs accordingly. Unavail-
ability of medication in Tanzania is a common problem, 
also affecting other health sectors including maternal and 
child health [19]. The unreliability of getting psychotropic 
medication compromises the timely provision of quality 
mental health care.
On the other hand, antiepileptic medications were said 
to be most available compared to other psychotropic 
medications. The reason for this variation in availabil-
ity is not known, although in Zambia, social programs 
aimed at encouraging people with epilepsy to visit health 
facilities must have increased patient’s access to antie-
pileptic medication [20]. In Tanzania, patients with epi-
lepsy attend the same outpatient clinic with patients with 
mental illness and that they all receive the same benefits 
including free medication as that provided for mental 
illness. Furthermore, in Gambia and other West Afri-
can countries, it is reported that lack of demand associ-
ated with the considerable cost-implications of treating 
patient with mental illness and the absence of prescrib-
ers are the reason for lack of availability of psychotropic 
medication [21]. In Tanzania, patients with epilepsy 
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attend the same outpatient clinic with patients with men-
tal illness and they all receive the same benefits including 
free medication as that provided for mental illness.
Multiple approaches should be used to address chal-
lenges within the health system that prevent access to 
essential medication for mental health. There should be 
a special focus on improving the governance of the medi-
cation delivery system so that it promotes the account-
ability of key stakeholders, transparency, especially in the 
dealing with information and medication funds, as well 
as participation in decision making over the allocation of 
medication funds.
The government also needs to emphasize on imple-
mentation of its policy especially on the use of the basic 
essential medicine kits that ensure availability of all 
medicines in primary health services. This could help 
in alleviating the medicine shortage in most of areas 
in the country. Although hospitals have been given 
the mandate of ordering medicines they need, mental 
health services suffer with lack of financial support. In 
this study, the hospital management was reported to set 
aside very low financial budget for mental health. This 
is partly due to the stigmatizing nature of mental ill-
ness among health care providers as reported in other 
studies [22–24] and partly due to limited budget. There 
is a need for the ministry of health to increase and 
strengthen the budget for health in the districts. The 
council health management team (CHMT) needs to set 
aside enough money in the budget for mental health to 
help in improve the availability and accessibility to psy-
chotropic medications.
Financial concerns towards psychotropic medications
Health insurance for mental health in many low- and 
middle-income countries has not yet been extensively 
practiced. The goals of health insurance are to make 
health services more affordable through the use of pub-
lic subsidies. In this study, most mentally ill patients were 
not covered by national health insurance scheme. This is 
because the coverage of national health insurance scheme 
is very limited. According to the Ministry of Health, 
Community Development, Gender, Elderly and Children 
(MoHCDGEC), the l health insurance scheme for public 
servants covers only 20% of the total population. Medi-
cines are covered by insurance but its availability in the 
treatment facilities is a which needs to be addressed [25]. 
In other countries, studies have shown strong evidence 
that health insurance increases financial protection by 
reducing out-of-pocket spending [26] which relieves 
patients with mental illness
It was reported in this study that patients and car-
egivers could not afford to buy medication due to the 
poor economic situation of the family members and the 
patient. This can be explained by the fact that the men-
tal disorders usually are chronic diseases that make the 
patients and caregivers spend too much of their savings 
to treat the illness. Cost analysis in India revealed that 
some specific brands of psychotropic medication are 
expensive and difficult to buy even though it is effective 
for alleviating the symptoms of mental illness [18]. This 
reveals an important aspect which is for prescribers to 
be aware of the ability of their patients and caregivers to 
afford that medication before prescribing.
It is also reported that strong social and financial 
support increases the likelihood of the patient buying 
medications. The support from relatives or other peo-
ple around the patient is needed, as it is important both 
for physical and psychological relief, especially when 
directed towards assistance in buying prescribed medi-
cation. It is known that lack of support for patients with 
mental illness living in the community is a problem [27, 
28]. The reason for this in Tanzania is not fully under-
stood. Most of patients and caregivers in this study have 
reported poverty as contributing factor. In Ghana, the 
caregivers indicated that lack of surplus money, stigma, 
and lack of empathy to be important factors contributing 
to poor social and financial support [29].
It is difficult to provide financial support to the 
patients, especially that which is needed for medication. 
Even when the support is available, it cannot be sustained 
because mental illness tends to be chronic and needs a 
continued supply and use of prescribed medication.
Coverage of free treatment policy
It revealed from this study that people with mental illness 
are included in free treatment package according to the 
National Health Policy [30]. The other group includes the 
elderly, children and maternal health services. According 
to this policy, these are the low income population who 
obtain their subsistence through their dependants. The 
patients in these groups are exempted from cost sharing 
and other related health charges such as lab investiga-
tions and consultation fees. However, the coverage of this 
service is very minimal with respect to patients in need. 
The reasons for ineffective exemption policy in Tanza-
nia is not clearly known although lack of commitment of 
health managers, confusion about the eligibility criteria, 
failure of central government to establish clear eligibil-
ity criteria and limited technical support are some of the 
reasons reported in other studies [31, 32]. The availability 
of free treatment has not been realistic in terms of access 
to free medications for patient with mental illness. Inad-
equate supply of medication is the main stumping stone 
for quality mental health services.
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Limitation of the study
The lack of psychiatrists in the participant group is one of 
the limitations of the study. This would probably give dif-
ferent perspectives and expertise on areas of prescribing 
practice. The study is also limited by lack of pharmacists 
in the participant group who could discuss the experi-
ence of dispensing psychotropic medication. Finally, the 
study is based on only one district which may have lim-
ited representation of the other districts in the country.
Conclusion
Availability and affordability of psychotropic medication 
for patients were shown to be inadequate in this study. 
This was attributed to insufficient funds to support the 
health facilities and technical challenges contributed by 
both by the health facilities and stakeholders. To improve 
mental health services in the country, it is important 
to ensure adequate and regular supply of psychotropic 
medications for mental health. Essential psychotropic 
medicines were usually unavailable in the health facil-
ity. Access to psychotropic medications is essential to 
address the public health burden attributed to untreated 
mental illnesses. These findings call for the government 
to increase funds allocated specifically for buying essen-
tial psychotropic medications and improving the process 
of procurement and supply.
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